Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Obermeier

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Psychiatry Research|February 29, 2012
The CNR1 gene in depression and schizophrenia - is there an association with early improvement and response?Rebecca Schennach, Peter Zill, Michael Obermeier, et al.
European Archives of Psychiatry and Clinical Neuroscience|March 5, 2014
Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factorsFlorian Seemüller, Sebastian Meier, Michael Obermeier, et al.
European Archives of Psychiatry and Clinical Neuroscience|September 12, 2012
No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depressionRichard Musil, Peter Zill, Florian Seemüller, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 26, 2010
Outcomes of 1014 naturalistically treated inpatients with major depressive episodeFlorian Seemüller, Michael Riedel, Michael Obermeier, et al.
The Psychiatric Quarterly|November 1, 2011
Remission and recovery and their predictors in schizophrenia spectrum disorder: results from a 1-year follow-up naturalistic trialRebecca Schennach, Michael Riedel, Michael Obermeier, et al.
Psychopathology|July 17, 2012
Evaluating depressive symptoms in schizophrenia: a psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating ScaleRebecca Schennach, Michael Obermeier, Florian Seemüller, et al.
Schizophrenia Research|June 30, 2009
Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disordersRebecca Schennach-Wolff, Markus Jäger, Florian Seemüller, et al.
Journal of Psychiatric Research|June 10, 2009
Attitude towards adherence in patients with schizophrenia at dischargeRebecca Schennach-Wolff, Markus Jäger, Florian Seemüller, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|April 13, 2010
Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?Rebecca Schennach-Wolff, Markus Jäger, Michael Obermeier, et al.
Psychiatric Services (Washington, D.C.)|January 10, 2012
Predictors of relapse in the year after hospital discharge among patients with schizophreniaRebecca Schennach, Michael Obermeier, Sebastian Meyer, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Psychiatry Research|February 29, 2012
The CNR1 gene in depression and schizophrenia - is there an association with early improvement and response?Rebecca Schennach, Peter Zill, Michael Obermeier, et al.
European Archives of Psychiatry and Clinical Neuroscience|March 5, 2014
Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factorsFlorian Seemüller, Sebastian Meier, Michael Obermeier, et al.
European Archives of Psychiatry and Clinical Neuroscience|September 12, 2012
No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depressionRichard Musil, Peter Zill, Florian Seemüller, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 26, 2010
Outcomes of 1014 naturalistically treated inpatients with major depressive episodeFlorian Seemüller, Michael Riedel, Michael Obermeier, et al.
The Psychiatric Quarterly|November 1, 2011
Remission and recovery and their predictors in schizophrenia spectrum disorder: results from a 1-year follow-up naturalistic trialRebecca Schennach, Michael Riedel, Michael Obermeier, et al.
Psychopathology|July 17, 2012
Evaluating depressive symptoms in schizophrenia: a psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating ScaleRebecca Schennach, Michael Obermeier, Florian Seemüller, et al.
Schizophrenia Research|June 30, 2009
Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disordersRebecca Schennach-Wolff, Markus Jäger, Florian Seemüller, et al.
Journal of Psychiatric Research|June 10, 2009
Attitude towards adherence in patients with schizophrenia at dischargeRebecca Schennach-Wolff, Markus Jäger, Florian Seemüller, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|April 13, 2010
Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?Rebecca Schennach-Wolff, Markus Jäger, Michael Obermeier, et al.
Psychiatric Services (Washington, D.C.)|January 10, 2012
Predictors of relapse in the year after hospital discharge among patients with schizophreniaRebecca Schennach, Michael Obermeier, Sebastian Meyer, et al.
Pageof 7